Evaluating OWise: the digital patient experience platform aimed at improving cancer outcomes
Lead Participant:
PX HEALTHCARE LIMITED
Abstract
"Today there are 2.5 million people living with cancer in the UK and this is forecast to exceed 4 million in 2030\. Annual NHS costs for cancer services are £5 billion, but the cost to society is £18.3 billion. As so many people live with cancer, quality of life is ever more important as is the need to accurately understand how cancer patients experience treatments to improve outcomes.
Px HealthCare (called Px, which stands for Patient Experience) has developed OWise ([www.owise.uk][0]), a mobile platform supporting cancer patients. OWise is a real game-changer as
* its award-winning app has shown to empower patients during treatment and improve the patient-doctor interaction (Young-Afat et al. 2016),
* while the fully anonymised real time Patient Reported Outcome (PRO) data are investigated using advanced data-analytics to improve oncology outcomes.
OWise breast cancer, which is supported by the NHS Innovation Accelerator, was launched in the UK in 2016\. A Dutch evaluation study demonstrated that 90% of patients and clinicians would recommend OWise to patients. It is free for use and is the only cancer app listed in the NHS Digital Tools Library.In the Five Year Forward View, the NHS has set out its ambition to help people to manage their own health, with self care playing an important role. A helpful measure to assess how well people to manage their own health and wellbeing is called patient activation.
To quantify the impact of OWise on breast cancer patients' clinical outcomes and on a possible reduction in the use of NHS resources, more research is needed, particularly on patient activation, quality of life and unplanned hospital admissions in the UK.
The present proposal brings together the developers of OWise with an extraordinary group of clinicians and researchers from the Royal Marsden Hospital, the Institute of Cancer Research and Imperial College Health Partners, aiming to generate the evidence around the impact of OWise on patient activation using a comparative study design.
[0]: http://www.owise.uk"
Px HealthCare (called Px, which stands for Patient Experience) has developed OWise ([www.owise.uk][0]), a mobile platform supporting cancer patients. OWise is a real game-changer as
* its award-winning app has shown to empower patients during treatment and improve the patient-doctor interaction (Young-Afat et al. 2016),
* while the fully anonymised real time Patient Reported Outcome (PRO) data are investigated using advanced data-analytics to improve oncology outcomes.
OWise breast cancer, which is supported by the NHS Innovation Accelerator, was launched in the UK in 2016\. A Dutch evaluation study demonstrated that 90% of patients and clinicians would recommend OWise to patients. It is free for use and is the only cancer app listed in the NHS Digital Tools Library.In the Five Year Forward View, the NHS has set out its ambition to help people to manage their own health, with self care playing an important role. A helpful measure to assess how well people to manage their own health and wellbeing is called patient activation.
To quantify the impact of OWise on breast cancer patients' clinical outcomes and on a possible reduction in the use of NHS resources, more research is needed, particularly on patient activation, quality of life and unplanned hospital admissions in the UK.
The present proposal brings together the developers of OWise with an extraordinary group of clinicians and researchers from the Royal Marsden Hospital, the Institute of Cancer Research and Imperial College Health Partners, aiming to generate the evidence around the impact of OWise on patient activation using a comparative study design.
[0]: http://www.owise.uk"
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| PX HEALTHCARE LIMITED | £79,714 | £ 39,857 |
Participant |
||
| THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST |
People |
ORCID iD |
| Anne Bruinvels (Project Manager) |